Variantyx News & Events

News: Variantyx and FDNA Announce Integration of their Applications to Facilitate Rare Disease Diagnosis


August 30, 2017. Framingham, MA.

Variantyx today announced integration of its clinical whole genome testing pipeline with FDNA’s Face2Gene suite of applications. Using its proprietary Genomic Intelligence® platform, Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on comprehensive whole genome sequencing (WGS). Integration with Face2Gene technology now enables clinicians worldwide to send information about the phenotypes, syndromes and genes that correlate with a patient’s facial and clinical analysis to Variantyx directly, speeding analysis and improving variant interpretation.

Read More ...

News: Variantyx Launches Genomic Intelligence® Clinical Diagnostic Platform

Genomic Intelligence

March 21, 2017. Framingham, MA.

Variantyx announced the US launch of its proprietary clinical diagnostic platform at the American College of Medical Genetics (ACMG) conference in Phoenix, AZ. The Genomic Intelligence® platform automates the complete NGS testing process from sample collection to sequencing, data analysis, interpretation and clinical report generation, allowing ordering physicians to focus on making a diagnosis with the interactive support of Variantyx’ US Board Certified Geneticists. The end-to-end clinical diagnostic services are errors and omissions insured and HIPAA compliant.

Read More ...
Scroll Up